Repair of Lateral And Mediolateral Episiotomy
Launched by AIN SHAMS UNIVERSITY · Mar 27, 2018
Trial Information
Current as of May 01, 2025
Unknown status
Keywords
ClinConnect Summary
Aim of the work:
This study aims to compare between postoperative pain following repair of episiotomy by continuous or interrupted suturing.
Study population:
All primipara full term women with episiotomy done in a selective rather than liberal use.
E- Patients in the study will be randomized into one of two groups either those who have:
1. Interrupted technique of episiotomy repair or
2. Continuous knotless suturing technique and each of the two groups will be subdivided into either medio-lateral or lateral episiotomy.
The Episiotomy in group A will be done using the interrupted sutu...
Gender
FEMALE
Eligibility criteria
- Inclusion criteria:
- • 1. Primipara women.
- • 2. Fullterm pregnancy.
- • 3. Lateral or mediolateral episiotomy done in selective rather than liberal episiotomy.
- Exclusion Criteria:
- • 1. Risk factor of trauma eg; macrosomia, congenital fetal malformations as (exophthalmous major, hydrocephalus, spinal cord teratoma....etc.
- • 2. Instrumental delivery.
- • 3. Primipara refuses to be in the study.
- • 4. Other techniques of episiotomy.
- • 5. Preterm onset of labour.
- • 6. Indication for CS eg; CPD, malposition and malpresentation, fetal distress....etc.
- • 7. Use of epidural analgesics.
- • 8. Factors affecting wound healing eg;DM, corticosteroid therapy, chronic debilitating diseases...etc.
About Ain Shams University
Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials